NCT04138979 is a clinical trial of cyclophosphamide in Microbiota, sponsored by First Affiliated Hospital of Harbin Medical University.

Who is sponsoring NCT04138979?

NCT04138979 is sponsored by First Affiliated Hospital of Harbin Medical University.

What drugs are being tested in NCT04138979?

Interventions in NCT04138979: cyclophosphamide.

What condition does NCT04138979 study?

NCT04138979 studies Microbiota.

Is NCT04138979 still recruiting?

NCT04138979 is currently status unknown. Last updated 25 October 2019.

Last reviewed 2019-10-25 · How we verify

NCT04138979

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy

Status unknown Last updated 25 October 2019

What this trial tests

trial testing cyclophosphamide in Microbiota in 80 participants. Status unknown.

Timeline

12 September 2019

Primary endpoint
15 October 2020

15 October 2020

Quick facts

Lead sponsor	First Affiliated Hospital of Harbin Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	80
Start date	12 September 2019
Primary completion	15 October 2020
Estimated completion	15 October 2020
Sites	1 location across China

Drugs / interventions tested

cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Microbiota — all drugs for Microbiota →

Sponsor

First Affiliated Hospital of Harbin Medical University

Who can join

Adults 18 to 65, female only, with Microbiota. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To date, few studies have addressed the link between gut microbiota and breast cancer chemotherapy, and previous studies have only provided a link between the gut and breast cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Microbiome and Breast Cancer: New Role for an Ancient Population.
Eslami-S Z, Majidzadeh-A K, Halvaei S, Babapirali F, et al · · 2020 · cited 111× · PMID 32117767 · DOI 10.3389/fonc.2020.00120
Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer.
Brevi A, Cogrossi LL, Grazia G, Masciovecchio D, et al · · 2020 · cited 81× · PMID 33244315 · DOI 10.3389/fimmu.2020.565470
The gut microbiota in breast cancer development and treatment: The good, the bad, and the useful!
Nandi D, Parida S, Sharma D. · · 2023 · cited 55× · PMID 37305949 · DOI 10.1080/19490976.2023.2221452
Gut Microbiota and Breast Cancer: The Dual Role of Microbes.
Álvarez-Mercado AI, Del Valle Cano A, Fernández MF, Fontana L. · · 2023 · cited 50× · PMID 36672391 · DOI 10.3390/cancers15020443
Exploring the impact of gut microbiota and diet on breast cancer risk and progression.
Teng NMY, Price CA, McKee AM, Hall LJ, et al · · 2021 · cited 31× · PMID 33521932 · DOI 10.1002/ijc.33496
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy.
Aarnoutse R, Ziemons J, Hillege LE, de Vos-Geelen J, et al · · 2022 · cited 29× · PMID 35906259 · DOI 10.1038/s41523-022-00455-5
Gut microbiota interact with breast cancer therapeutics to modulate efficacy.
Arnone AA, Ansley K, Heeke AL, Howard-McNatt M, et al · · 2025 · cited 9× · PMID 39820166 · DOI 10.1038/s44321-024-00185-0
Microorganisms and Breast Cancer: An In-Depth Analysis of Clinical Studies.
Naderi N, Mosahebi A, Williams NR. · · 2023 · cited 2× · PMID 38276152 · DOI 10.3390/pathogens13010006

Verify or expand the search:

Other trials of cyclophosphamide

Trials testing the same drug.

NCT06904066 — Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W · Phase 1 · recruiting
NCT06865664 — FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma · Phase 1 · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06744504 — Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 · Phase 3 · recruiting
NCT06361329 — Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL · Phase 3 · recruiting

Other recruiting trials for Microbiota

Currently open trials in the same condition.

NCT07479511 — Adaptation of Lung Transplant Recipients at Extreme Altitude · active not recruiting
NCT07212361 — Infant Microbiota Restoration With Maternal Microbes · NA · recruiting
NCT07029360 — Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy · NA · recruiting
NCT06809660 — Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (P · NA · recruiting
NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting

Other First Affiliated Hospital of Harbin Medical University trials

Trials by the same sponsor.

NCT07020195 — QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease · NA · not yet recruiting
NCT06975592 — Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases · not yet recruiting
NCT06995456 — Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism · not yet recruiting
NCT07087093 — Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly · NA · recruiting
NCT06565845 — Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04138979 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Harbin Medical University
Last refreshed: 25 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04138979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing